Loading...
•
Sep 30, 2021
Harmony Biosciences Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021 and provided business updates.
Key Takeaways
Harmony Biosciences reported net product revenues of $80.7 million for the quarter ended September 30, 2021, a 77% increase compared to the same period in 2020. GAAP net loss available to shareholders was $9.6 million, or a loss of $0.17 per diluted share, while non-GAAP adjusted net income was $30.4 million, or $0.51 per diluted share.
WAKIX net revenue was $80.7 million for Q3 2021, a 77% increase compared to Q3 2020.
The average number of patients on WAKIX increased to approximately 3,500.
WAKIX was included in the American Academy of Sleep Medicine's updated clinical practice guideline.
A Phase 2 proof of concept clinical trial is evaluating pitolisant for EDS and other symptoms in patients with PWS, with top-line data expected in the first half of 2022.
Revenue by Segment
Forward Guidance
Harmony Biosciences did not provide specific forward guidance in this earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...